- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06232616
Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular Oedema
March 11, 2024 updated by: Shanghai Eye Disease Prevention and Treatment Center
Vitrectomy Combined With Intravitreal Dexamethasone Implant for the Treatment of Idiopathic Epiretinal Membrane With Cystoid Macular Oedema
The goal of this clinical trial is to evaluate the efficacy and safety of 25-gauge pars plana vitrectomy combined with intravitreal dexamethasone implant for the treatment of idiopathic epiretinal membrane with cystoid macular oedema. The main questions it aims to answer are:
- mean changes in best corrected visual acuity and central macular thickness from baseline to post-operative 24 weeks
- mean change in proportion of cystoid macular oedema area from baseline to post-operative 24 weeks
- intraocular pressure throughout postoperative 24 weeks
- concentrations of inflammatory factors in vitreous samples Participants will undergo a standard three-port 25-gauge pars plana vitrectomy and epiretinal membrane peeling combined with phacoemulsification, aspiration, and intraocular lens implantation. The dexamethasone implant will be injected into the vitreous cavity at the end of the operation.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Tao Sun, Ph.D.
- Phone Number: +8618916576690
- Email: drsuntao@yeah.net
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200040
- Shanghai Eye Disease Prevention & Treatment Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- symptomatic patients aged 40 years or above with idiopathic stage 3-4 epiretinal membrane defined on the basis of spectral-domain optical coherence tomography classification;
- central retinal thickness >300 µm;
- cystoid oedema within a 1 mm diameter range with the macular fovea as the center;
- ocular axial length less than 25.00 mm.
Exclusion Criteria:
- concomitant or previous macular diseases that may hinder visual improvement other than epiretinal membrane (e.g., age-associated macular degeneration, retinal vein occlusion, or diabetic macular oedema);
- previous vitreoretinal surgery or intravitreal injection history;
- history of glaucoma or optic neuropathy of any kind;
- patients with uncontrolled systemic diseases or infectious diseases;
- patients who took medicines that may have ocular side effects, such as glucocorticoid or hydroxychloroquine.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm
In this single-arm designed study, participants with idiopathic epiretinal membranes with macular oedema were assigned a vitrectomy with an intravitreal dexamethasone implant.
|
The dexamethasone implant will be injected into the vitreous cavity at the end of the surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
improvement of visual acuity
Time Frame: from baseline to postoperative 24 weeks
|
mean change in best corrected visual acuity
|
from baseline to postoperative 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Tao Sun, Ph.D., Shanghai Eye Diseases Prevention & Treatment Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 11, 2024
Primary Completion (Estimated)
December 31, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
January 4, 2024
First Submitted That Met QC Criteria
January 28, 2024
First Posted (Actual)
January 31, 2024
Study Record Updates
Last Update Posted (Actual)
March 12, 2024
Last Update Submitted That Met QC Criteria
March 11, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Macular Degeneration
- Macular Edema
- Epiretinal Membrane
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- YFZXYDK202401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
mean change in best corrected visual acuity throughout the study until the results are published in the journal.
IPD Sharing Time Frame
after the results are published in the journal.
IPD Sharing Access Criteria
E-mail contact
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epiretinal Membrane
-
Medical University of GrazCompletedEpiretinal Membrane of Both EyesAustria
-
Centre Hospitalier Universitaire DijonTerminatedEpiretinal Membrane SurgeryFrance
-
University of RegensburgCompletedIdiopathic Epiretinal Membrane, CataractGermany
-
Centre Hospitalier Universitaire DijonCompletedEpiretinal Membranes
-
Centre Hospitalier Universitaire DijonRecruitingSurgery for Cataract | Surgery for and Idiopathic Epiretinal MembraneFrance
-
Vienna Institute for Research in Ocular SurgeryCompleted
-
The Ludwig Boltzmann Institute of Retinology and...Completed
-
Nantes University HospitalCompleted
-
IRCCS Policlinico S. MatteoCompleted
-
Changhua Christian HospitalCompletedEpiretinal Membrane | Internal Limiting Membrane WrinklingTaiwan
Clinical Trials on vitrectomy combined with intravitreal dexamethasone implant
-
Tianjin Medical University Eye HospitalRecruitingDiabetic Macular Edema | Pars Plana Vitrectomy | ConberceptChina
-
Wenzhou Medical UniversityCompleted
-
Barnes Retina InstituteAllerganTerminatedMacular Edema | Epiretinal MembraneUnited States
-
Anders KvantaCompletedProliferative Diabetic RetinopathySweden
-
Centre Hospitalier Universitaire DijonRecruiting
-
Cairo UniversityCompletedImmediate Dental Implants Connective Tissue Graft Esthetic ZoneEgypt
-
AllerganCompletedMacular Edema | Retinal Vein OcclusionSouth Africa, Canada, United States, Australia, Israel
-
Zagazig UniversityCompletedCombined Viscocanalostomy, Phacoemulsification, OIogen Implant in Open Angle Glaucoma (Visco-ologen)Primary Open-angle GlaucomaEgypt
-
Aerie PharmaceuticalsCompletedMacular EdemaUnited States
-
University of PennsylvaniaMassachusetts General HospitalRecruitingAlzheimer's DiseaseUnited States